Allgemeine Baugenossenschaft Zürich (ABZ), a non-profit housing cooperative, launched and priced its issuance of CHF 120 million total nominal amount of 0.25% Sustainability Bonds 2021-2031. The bonds have been offered in full compliance with the Financial Services Act. Zürcher Kantonalbank acted as sole lead manager. Application will be made for the listing of the […]
Invesco Physical Markets Public Limited Company listed a new physical gold exchange-traded product (ETP) on SIX Swiss Exchange, on 27th August, 2021. Lenz & Staehelin assisted Invesco with all Swiss regulatory aspects for the listing
HBM Healthcare Investments successfully issued CHF 100 million 1.125 per cent Bonds due 2027. The bonds will be admitted for trading and listing on the SIX Swiss Exchange. The advisors Homburger acted as counsel to HBM Healthcare
Biopharmaceutical company Relief Theraputics Holding, has a binding agreement with two institutional U.S. investors completed. The contract provides for the purchase of Relief shares with a total value of CHF 15 million, which come from
UBS Group completed its issuance of USD 2 billion in aggregate principal amount of fixed rate/fixed rate senior notes due August 2027 under its senior debt programme. The notes are bail-inable (TLAC) bonds that are eligible
UBS, acting through its London branch, successfully completed its issuance of (i) USD 1 bn aggregate principal amount of Floating Rate Notes due August 2024, and (ii) USD 1 bn aggregate principal amount of 0.70 per cent. Notes due
Credit Suisse launched and completed, its registered offering of USD 3.75 bn aggregate principal amount of senior notes. The offering consisted of USD 1.4 billion aggregate principal amount of 0.520% senior notes due 2023, USD 1.75 billion aggregate principal amount
Niederer Kraft Frey (NKF) has advised Digital Realty, a global provider of carrier- and cloud-neutral data center, colocation and interconnection solutions on the offering of CHF 275 million of 0.20 percent bonds due 2026 and CHF 270 million of 0.55
Relief Therapeutics Holding, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, has issued 1,000,000,000 additional registered shares out of the authorised share capital approved by the Annual
H.C. Wainwright acted as sole placement agent in connection to the private placement of 71,428,572 shares in Relief Therapeutics Holding, a Swiss biopharmaceutical company listed at SIX Swiss Exchange, at a price of CHF 0.21 per
